EN2 (Engrailed-2) is a homeobox-containing transcription factor encoded by the *EN2* gene, primarily known for its role in embryonic development, particularly in the patterning of the midbrain-hindbrain region and cerebellar development. Initially studied in neurodevelopment, EN2 has gained attention in cancer research due to its aberrant expression in malignancies such as prostate, breast, and lung cancers. In tumors, EN2 acts as an oncoprotein, promoting cell proliferation, invasion, and metastasis while suppressing apoptosis. Its expression in cancer cells correlates with advanced disease stages and poor prognosis, suggesting potential utility as a diagnostic or prognostic biomarker.
EN2 antibodies are tools developed to detect and quantify EN2 protein levels in research and clinical contexts. Polyclonal and monoclonal EN2 antibodies are used in techniques like immunohistochemistry, Western blotting, and ELISA to study EN2 localization, expression patterns, and interactions. In prostate cancer, EN2 antibodies have been pivotal in identifying secretory EN2 in urine, a non-invasive diagnostic marker. Additionally, EN2-targeting antibodies are being explored for therapeutic applications, including antibody-drug conjugates or immune-based therapies. Beyond oncology, EN2 antibodies contribute to neuroscience research, elucidating its role in neurodegenerative disorders like Alzheimer’s disease. Despite progress, challenges remain in standardizing antibody specificity and optimizing clinical translation.